和黄医药(00013.HK)爱优特联合达伯舒获批准用于治疗晚期子宫内膜癌

阿斯达克财经
03 Dec 2024

和黄医药(00013.HK) 公布,与信达生物(01801.HK) 联合宣布爱优特(呋喹替尼)与达伯舒(信迪利单抗注射液)联合疗法用于治疗既往系统性抗肿瘤治疗后失败且不适合进行根治性手术治疗或根治性放疗的晚期错配修复完整的子宫内膜癌患者的新药上市申请在中国获附条件批准。此前,该联合疗法获国家药监局纳入优先评审及突破性治疗品种。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-03 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10